A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as Add-on Therapy in Adult Subjects With Epilepsy Consisting of Uncontrolled Partial-Onset Seizures

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as Add-on Therapy in Adult Subjects With Epilepsy Consisting of Uncontrolled Partial-Onset Seizures

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Ganaxolone (Primary)
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Sponsors Marinus Pharmaceuticals
  • Most Recent Events

    • 23 Feb 2017 Results assessing safety and efficacy of a new formulation of ganaxolone, published in the Epilepsia.
    • 07 Dec 2015 According to a Marinus Pharmaceuticals media release, additional responder analysis data was presented at the 69th Annual Meeting of the American Epilepsy Society.
    • 07 Dec 2015 Additional responder analysis data was published in a Marinus Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top